Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate for the acute treatment of migraine.

"In our Phase 2 clinical trial, MAP0004 demonstrated the potential to be both fast acting and long-lasting, providing pain relief in as fast as ten minutes with relief lasting for 24 and 48 hours, so we believe that MAP0004 has the potential to be a first-line therapy for migraine patients. We would like to thank our investigators as well as their patients for their strong interest and support for studying the potential benefits of MAP0004," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to announcing clinical data from the efficacy portion of the trial in the first half of this year."

The Phase 3 multi-center, randomized, double-blind, placebo-controlled trial in approximately 850 migraine sufferers is evaluating the safety and efficacy of MAP0004 as a potential acute treatment for migraine. The primary efficacy endpoints are pain relief and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. The study is also evaluating earliest onset of pain relief, pain relief at 10 minutes, and sustained pain relief and freedom at 24 and 48 hours. Patients enrolled in the trial are being evaluated for the treatment of a single migraine and may continue in a long-term safety arm of the trial, enrollment in which is ongoing. MAP Pharmaceuticals is conducting this first Phase 3 trial pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.

MAP0004 is a novel, o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
(Date:8/21/2014)... has observed tiny quantum vortices in cold droplets of ... Science that the exotic vortices arrange themselves as ... first time that the quantum vortices, which have already ... as superfluid helium, have been detected in nanodroplets. "The ... of the University of Southern California, one of the ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... and Mexico ... several newly approved agents, the anticipated label extension ... the launch of emerging biologics will substantially increase ... the emerging IL-5 inhibitors will introduce a new dynamic ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... . , What would be a case for ... for a micro engine. If it sputters, this is caused ... with its running. Researchers at the University of Stuttgart and ... observed this with a heat engine on the micrometre scale. ...
... Dec. 12, 2011  Kensey Nash Corporation (Nasdaq: ... by Spectranetics Corporation (Nasdaq: SPNC ) that ... of the endovascular product lines purchased from Kensey Nash ... $6 million milestone payable to Kensey Nash.  As previously ...
... 12, 2011  Fox Insurance Company, a Medicare Part D ... judgment in the arbitration between the company and ProCare, ... million, following a suit against ProCare based on Fox,s ... Nathan M. Barotz, chairman of Fox Insurance Company ...
Cached Biology Technology:The world's smallest steam engine 2The world's smallest steam engine 3Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2
(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. ... growing mobile commerce market, announced today that its shares ... stock to be issued in its proposed underwritten public ... for listing on The Nasdaq Capital Market, subject to ... common stock and warrants, and will trade under the ...
(Date:8/21/2014)... Fla. , Aug. 21, 2014 /PRNewswire-iReach/ ... that it has agreed to a partnership ... Orlando,s fastest growing Certified Nursing ... Gabriel Health Institute  an exclusive member of ... result, Binary Biometrics will improve its service ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... more intense rainstorms and more frequent heat waves are ... when climate change is mentioned. Now, two University of ... transmission in wild birds can be added to the ... used a mathematical model to explore the consequences of ...
... of beetles and only two species of the tuatara, a ... Zealand. Crocodiles and alligators, while nearly 250 million years old, ... "winners" including mammals and many species of birds and ... biology. Scientists have often posited that because ...
... marine whelk, Solenosteira macrospira . He does all the work ... few of the baby snails are his own. The surprising ... S. macrospira in a small club of ... and sibling cannibalism, and the species has one of the most ...
Cached Biology News:Climate change could increase levels of avian influenza in wild birds 2Climate change could increase levels of avian influenza in wild birds 3Why are there so many species of beetles and so few crocodiles? 2Why are there so many species of beetles and so few crocodiles? 3Male snails babysit for other dads 2Male snails babysit for other dads 3
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
... Object Parametric Analyzer and Sorter) large particle ... advantages of flow cytometry to applications that ... automated analysis and sorting. Our instruments ... traditional flow cytometers, but are designed to ...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
... raised against a partial recombinant ... SF3B2 (NP_006833, 592 a.a. ... protein with GST tag. ... NM_006842 Protein ...
Biology Products: